News About: Pharm. Industry
Keunwha to step up strategic alliance with Sandoz Korea
Keunwha Pharm says it plans to strengthen its bilateral ties with Sandoz Korea.
Keunwha signed a licensing agreement with Sandoz Korea to distribute Felodipine tablets 5mg for treatment of essential hypertension.
...
Price of Fuzeon to be determined
Pharmaceutical sources say that the Ministry for Health, Welfare and Family Affair committee will determine the price of Fuzeon, a new drug for AIDS.
The Health Insurance Review Agency says Fuzeon is an essential d...
Daewoong to step up OTC business
As pharmaceutical companies are competing to take a bigger stake in the domestic OTC market, Daewoong Pharm is activating its OTC business unit by separating it from ethical business unit.
“We are separating the tw...
Tanamin surpasses 120 million tablets in prescription
Yuyu Pharm says its blood circulation enhancer Tanamin (EGb 761) is emerging as one of the Korean’s popular prescription drugs.
Tanamin exceeded 120 million tablets in the quantity of prescription last year based o...
Novotech launches Korean unit
Novotech Inc says it established Novotech Asia Korea, its Korean unit, to offer clinical research services in Asia.
Novotech is the largest independent CRO in Australia. With operations in the US, Novotech is idea...
Health insurance reimbursement for hyperlipidemic treatment should be modified
The pharmacoeconomic issues of individual antihyperlipidemic agents should be evaluated in terms of various factors, according to the Korean Society of Cardiology and the Korean Society of Lipidology and Atheroscleros...
SK teams up with MSD Korea over losartan
SK Chemicals and MSD Korea entered into an agreement to conduct the joint marketing of COSKAR PLUS and COSKAR PLUS F on April 24.
COSKAR PLUS and COSKAR PLUS F contain losartan, which has been marketed by the trade...
Wholesalers, GSK reach accord over margin issue
The Pharmaceutical Development Consultative Committee and GlaxoSmithKline finally agreed on the need to step up efforts to narrow the differences on sensitive issues concerning the wholesaler margin, the Korea Associa...
Government to face another high price of new leukemia drug
The government will likely in a dilemma to determine the price of Tasigna, another leukemia drug produced by Novartis, as its Korean affiliate has applied to the Health Insurance Review Agency for a price evaluation.
...
Health insurance assessment system for new drugs triggers debate
The Health Insurance Review Agency's criteria to evaluate the effectiveness of anti-hyperlipemic agents in order to decide whether they are eligible for the list has been under fire as it could reduce the price of...
